As our planet's population continues to grow and age, finding new and innovative healthcare solutions will be paramount. However, it takes a lot of work and money in order to get a new drug to market. From beginning research to running clinical trials, creating new therapies is a daunting task. This intensive process is one of the major reasons why healthcare costs have eclipsed the rate of inflation over the last 20 years. In order to save on expenses, a variety of biotech and drug manufacturers have started outsourcing various steps in the process to a group of independent lab firms. These contract research organizations (CROs) are finally beginning to attract investor attention and could be a great way to play healthcare's growth.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Big Money in Outsourcing
With more than $106.9 billion worth of annual branded drugs sales coming off patent, from now until 2020, Big Pharma needs to reinvent its pipeline. This is driving an average projected 3.6% to 8% growth in R&D budgets among drug makers and biotechs. However, at the same time, prices for creating these therapies has surged exponentially. New high tech sequencing, further regulation from the FDA and "difficult to crack" diseases have all pushed development costs higher and higher. In order to combat these expenditures, many drug makers have started to outsource steps along the way. (For related reading, see How To Do Qualitative Analysis On Biotech Companies.)

And there's big money for those firms that run all of these clinical trials. According to data from IMS Health, outsourcing drug trials and basic lab work is currently a $60 billion market opportunity. More than 27% of the largest drug makers expect to outsource trials in 2012, while almost half of the smallest biotech companies expect to do likewise. With expanding R&D budgets and rising costs, the CROs are in a sweet spot to profit.

Analysts at Morningstar (Nasdaq:MORN) expect growth in the CRO industry to continue accelerating throughout 2012. The industry has started to adopt a strategic partnership model that will ultimately benefit the sector long-term. This has allowed major drug makers to pair up with leading CROs as long-term partners in research and development. In addition, private-equity buyers have shown a certain enthusiasm for CROs of late and started to gobble them up at premiums. Private equity firms, the Carlyle Group and Hellman & Friedman, recently agreed to pay $3.9 billion in cash to buy Pharmaceutical Product Development.

Running Your Own Trials
For investors, the contract research firms could be a great way to play healthcare's long term picture. While some broad-based biotech ETFs, like the Market Vectors Biotech ETF (ARCA:BBH), do contain some exposure to CROs such as Charles River Laboratories (NYSE:CRL), that exposure is limited. The best way to play is through individual holdings.

Partnering with pharma giant Pfizer (NYSE:PFE), ICON plc (Nasdaq:ICLR) is a great example in the sector. The company has the global scale needed to succeed in the ever-increasing complex regulatory environment and the firm expects to grow revenues 9% annually. In addition, the firm has a healthy cash balance and due to where it is domiciled (Ireland), the company's shares are trading at a discount. Similarly, CRO PAREXEL (Nasdaq:PRXL) has also partnered with Pfizer.

Chinese CRO WuXi PharmaTech (NYSE:WX) has seen its revenues rise as the firm has started expanding its manufacturing operations throughout the R&D process. The CRO is responsible for manufacturing hepatitis C therapy Incivek for Vertex (Nasdaq:VRTX) and Johnson & Johnson (NYSE:JNJ), and will continue to benefit from China's low wages and drug developers' need to cut costs. (For related reading, see A Primer On The Biotech Sector.)

Bottom Line
As drug makers need to beef up their pipelines in world of rising costs, the contract research sector will continue to see its stars shine. The previously mentioned firms are great ways to play the need for outsourcing and cost cutting.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Chart Advisor

    Now Could Be The Time To Buy IPOs

    There has been lots of hype around the IPO market lately. We'll take a look at whether now is the time to buy.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Chart Advisor

    Copper Continues Its Descent

    Copper prices have been under pressure lately and based on these charts it doesn't seem that it will reverse any time soon.
  4. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  5. Mutual Funds & ETFs

    Buying Vanguard Mutual Funds Vs. ETFs

    Learn about the differences between Vanguard's mutual fund and ETF products, and discover which may be more appropriate for investors.
  6. Mutual Funds & ETFs

    ETFs Vs. Mutual Funds: Choosing For Your Retirement

    Learn about the difference between using mutual funds versus ETFs for retirement, including which investment strategies and goals are best served by each.
  7. Mutual Funds & ETFs

    How to Reinvest Dividends from ETFs

    Learn about reinvesting ETF dividends, including the benefits and drawbacks of dividend reinvestment plans (DRIPs) and manual reinvestment.
  8. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  9. Mutual Funds & ETFs

    Best 3 Vanguard Funds that Track the Top 500 Companies

    Discover the three Vanguard funds tracking the S&P 500 Index, and learn about the characteristics and historical statistics of these funds.
  10. Forex Fundamentals

    How to Buy Chinese Yuan

    Discover the different options that are available to investors who want to obtain exposure to the Chinese yuan, including ETFs and ETNs.
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>

You May Also Like

Trading Center